Osel Devices Limited: 41 clinics shift hearing-aid mix
Key highlights
- OSEL reports 41 SFL clinics, with clinic average hearing-aid prices of ₹35,000 to ₹40,000 per device.
- Government tender hearing-aid units are priced at ₹2,500 to ₹3,000, versus ₹4,500 to ₹5,000 for entry-level retail devices.
- Hearing aids contributed about 35% of OSEL’s H1 FY27 revenue, compared with about 38% for LED displays.
- OSEL targets total exports of about ₹50 crore in FY27, up from about ₹23 crore in FY26.
powered by IRIS

Osel Devices Limited is using 41 SFL clinics to move hearing-aid sales toward direct patients, where clinic average prices are ₹35,000 to ₹40,000 per device versus ₹2,500 to ₹3,000 in government tenders. Management calls this channel shift its biggest margin lever in H1 FY27, when hearing aids accounted for about 35% of revenue.
Know OSEL Devices inside out
Results, valuation, peers and who's buying, in one view.
Why is OSEL moving hearing-aid sales through clinics?
OSEL is expanding clinic sales because the channel combines device revenue with testing, fitting and aftercare for individual patients. Its hearing-aid sales channels also include Government of India tenders under ADIP, white-label supply and exports, but the presentation identifies the 41 SFL clinics as its direct-patient route. Management says a patient served in a clinic is worth many times a tender unit.
The change forms part of OSEL’s stated move from manufacturing alone to customer relationships across its three verticals. In H1 FY27, hearing aids contributed about 35% of revenue, compared with about 38% from LED displays and about 27% from Philips Mobile. Management said H1 FY27 revenue rose 31.8% to ₹193.6 crore, while earnings before interest, tax, depreciation and amortisation, or EBITDA, rose 31.9% to ₹32.5 crore.
OSEL’s clinic proposition is distinct from supplying a tender: SFL clinics offer audiologist-led testing, fitting and aftercare alongside hearing-aid sales. The presentation does not disclose H1 FY27 clinic-device volumes, patient visits, revenue from SFL, or gross margin by sales channel. The disclosed price gap therefore shows the potential mix benefit rather than a reported clinic-margin result.
How do OSEL’s clinic prices compare with tender prices?
OSEL discloses clinic average prices of ₹35,000 to ₹40,000 per hearing aid, compared with ₹2,500 to ₹3,000 for a government-tender unit. It also identifies entry-level retail devices at ₹4,500 to ₹5,000, placing clinic pricing above both tender supply and entry retail. These are channel price ranges, not a like-for-like comparison of identical device specifications.
The table shows why management characterises value mix as the hearing-aid growth driver. OSEL says entry devices at ₹4,500 to ₹5,000 can deliver margins that double or triple versus a ₹2,500 tender unit, although it does not publish the underlying cost base. It does not make an equivalent margin disclosure for the ₹35,000 to ₹40,000 clinic average price.
Government tenders remain part of the model rather than a channel OSEL says it will leave. The company describes itself as the largest supplier to the Government of India in hearing aids, while listing tenders, SFL clinics, white-label buyers and Middle East and US exports as routes to market. The strategy is therefore a shift in sales mix toward patient relationships, not a disclosed withdrawal from institutional supply.
How did OSEL reach 41 SFL clinics?
OSEL reached 41 clinics through its March 2026 acquisition of a 90.69% interest in SFL Hearing Solutions and a Petals Healthcare partnership disclosed for May to July 2026. The group structure identifies SFL as a step-down subsidiary with 41 audiologist-staffed clinics. Management said the Petals arrangement took the SFL network to its current footprint.
The corporate structure separates retail expansion from the listed parent’s broader operations. OSEL Healthcare Pvt Ltd is a wholly owned subsidiary established for hearing-health retail and clinic expansion, and the presentation says its merger with SFL has been approved. This creates a disclosed path to combine SFL’s patient-facing network with OSEL’s hearing-aid manufacturing activity.
OSEL manufactures from Greater Noida and says it owns product design, engineering, sourcing, manufacturing, quality, installation and after-sales capabilities. Its Greater Noida facility became registered with the United States Food and Drug Administration in April 2026 and received ZED Gold between May and July 2026. Management links these credentials to export opportunities, rather than to a disclosed increase in clinic capacity.
Got a follow-up? Ask IRIS
What demand gap and execution milestones matter for OSEL?
OSEL is targeting a market in which about 88 million Indians need a hearing aid, while annual unit sales are only 8 lakh to 9 lakh, or about 1% of stated need. The presentation also says fewer than 3% of people with hearing loss are treated. These figures describe the addressable care gap, but they do not quantify how much of it OSEL’s 41 clinics can serve.
Availability of specialists is another constraint identified in the presentation. India has one audiologist per 5 lakh people, compared with one per 10,000 globally, while SFL’s 41 clinics are described as audiologist staffed. OSEL does not disclose its audiologist count, consultation volumes, clinic utilisation or the number of devices fitted at each location.
The presentation shows India’s hearing-aid market at US$248.0 million in 2025, US$264.5 million in 2026 and US$396.4 million in 2034, representing a stated 5.19% compound annual growth rate. It also cites expected global value growth of 3% to 4% in 2026, driven by ageing. Those market estimates provide context for the clinic plan but are not OSEL revenue forecasts.
How does the clinic plan fit OSEL’s wider model?
OSEL presents clinics as one of three ways it is moving closer to customers: patient care in hearing health, recurring services and concessions in LED displays, and branded consumer distribution in mobile phones. Its content management system, or CMS, is billed at ₹700 to ₹800 per display per month and operates across more than 1,000 displays at more than 300 locations. This contrasts with the hearing strategy, where higher device prices are linked to the clinic channel.
In LED, OSEL’s 10-year Bharat Mandapam concession covers about 15,000 square feet of displays and is expected to add about ₹15 crore of annual revenue. In mobile, it sells through 268 distributors and more than 13,800 touchpoints, while the Philips S7221 5G launched in September 2026 at ₹20,499 and ₹22,499. These mechanisms support management’s stated aim of growing revenue and margins through deeper customer relationships across all three segments.
OSEL also targets total exports of about ₹50 crore in FY27, compared with about ₹23 crore in FY26. Management says LED original equipment manufacturer supply and hearing aids will lead that increase, so the target is not a hearing-aid-only measure. The planned 5.01-acre JNPA Special Economic Zone export and original equipment manufacturing hub is targeted for commercialisation from April 2027.
Conclusion
OSEL’s 41-clinic strategy changes the route to market for part of its hearing-aid business rather than replacing tender supply. The clinic channel offers testing, fitting and aftercare and carries a disclosed average device price of ₹35,000 to ₹40,000, far above the ₹2,500 to ₹3,000 tender range. With hearing aids contributing about 35% of H1 FY27 revenue, execution in this channel is material to the company’s stated value-mix plan.
The next disclosed milestones are the approved merger of SFL with OSEL Healthcare, progress toward the FY27 export target of about ₹50 crore, and commercialisation of the 5.01-acre JNPA Special Economic Zone hub from April 2027. OSEL has not disclosed clinic sales, utilisation, device volumes or channel-level profitability, leaving those measures unresolved as the network develops.


